CPT-11 is a clinically used cancer drug, and it is a prodrug of the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxycamptothecin). To bypass the need for the in vivo conversion of CPT-11 and increase the therapeutic index, bifunctional derivatives of SN-38 were prepared for use in antibody-based targeted therapy of cancer. The general synthetic scheme incorporated an acetylene-azide click cycloaddition step in the design, a short polyethylene glycol spacer for aqueous solubility, and a maleimide group for conjugation. Conjugates of a humanized anti-CEACAM5 monoclonal antibody, hMN-14, prepared using these SN-38 derivatives were evaluated in vitro for stability in buffer and human serum and for antigen-binding and cytotoxicity in a human colon adenocarcinoma cell line. Conjugates of hMN-14 and SN-38 derivatives 16 and 17 were found promising for further development.
CPT-11 is a clinically used n class="Disease">cancer drug, and it is a prodrug of the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxycamptothecin). To bypass the need for the in vivo conversion of CPT-11 and increase the therapeutic index, bifunctional derivatives of SN-38 were prepared for use in antibody-based targeted therapy of cancer. The general synthetic scheme incorporated an acetylene-azide click cycloaddition step in the design, a short polyethylene glycol spacer for aqueous solubility, and a maleimide group for conjugation. Conjugates of a humanized anti-CEACAM5 monoclonal antibody, hMN-14, prepared using these SN-38 derivatives were evaluated in vitro for stability in buffer and human serum and for antigen-binding and cytotoxicity in a humancolon adenocarcinoma cell line. Conjugates of hMN-14 and SN-38 derivatives 16 and 17 were found promising for further development.
Authors: Michael A Walker; Gene M Dubowchik; Sandra J Hofstead; Pamela A Trail; Raymond A Firestone Journal: Bioorg Med Chem Lett Date: 2002-01-21 Impact factor: 2.823
Authors: Philip R Hamann; Lois M Hinman; Irwin Hollander; Carl F Beyer; Delores Lindh; Ryan Holcomb; William Hallett; Hwei-Ru Tsou; Janis Upeslacis; Dan Shochat; Andrew Mountain; David A Flowers; Irwin Bernstein Journal: Bioconjug Chem Date: 2002 Jan-Feb Impact factor: 4.774
Authors: J W Singer; P De Vries; R Bhatt; J Tulinsky; P Klein; C Li; L Milas; R A Lewis; S Wallace Journal: Ann N Y Acad Sci Date: 2000 Impact factor: 5.691
Authors: R H Mathijssen; R J van Alphen; J Verweij; W J Loos; K Nooter; G Stoter; A Sparreboom Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531
Authors: S Okuno; M Harada; T Yano; S Yano; S Kiuchi; N Tsuda; Y Sakamura; J Imai; T Kawaguchi; K Tsujihara Journal: Cancer Res Date: 2000-06-01 Impact factor: 12.701
Authors: Gene M Dubowchik; Raymond A Firestone; Linda Padilla; David Willner; Sandra J Hofstead; Kathleen Mosure; Jay O Knipe; Shirley J Lasch; Pamela A Trail Journal: Bioconjug Chem Date: 2002 Jul-Aug Impact factor: 4.774
Authors: Moreno Zamai; Martin VandeVen; Mariella Farao; Enrico Gratton; Alberto Ghiglieri; Maria G Castelli; Erminia Fontana; Roland D'Argy; Antonio Fiorino; Enrico Pesenti; Antonino Suarato; Valeria R Caiolfa Journal: Mol Cancer Ther Date: 2003-01 Impact factor: 6.261
Authors: Robert P Lyon; Tim D Bovee; Svetlana O Doronina; Patrick J Burke; Joshua H Hunter; Haley D Neff-LaFord; Mechthild Jonas; Martha E Anderson; Jocelyn R Setter; Peter D Senter Journal: Nat Biotechnol Date: 2015-06-15 Impact factor: 54.908
Authors: Alexander N Starodub; Allyson J Ocean; Manish A Shah; Michael J Guarino; Vincent J Picozzi; Linda T Vahdat; Sajeve S Thomas; Serengulam V Govindan; Pius P Maliakal; William A Wegener; Steven A Hamburger; Robert M Sharkey; David M Goldenberg Journal: Clin Cancer Res Date: 2015-05-05 Impact factor: 12.531
Authors: Serengulam V Govindan; Thomas M Cardillo; Sung-Ju Moon; Hans J Hansen; David M Goldenberg Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531